Eris Lifesciences Limited accepted the resignation of Krishnakumar Vaidyanathan as Executive Director and Chief Operating Officer (COO), effective September 30, 2026. Vaidyanathan cited the need to pursue professional opportunities outside the company as the reason for his departure.

The company filed an intimation with stock exchanges on October 5, 2026, pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing followed an initial intimation dated September 11, 2026.

Resignation details and board acceptance

Vaidyanathan tendered his resignation to the Board of Directors on September 11, 2026. In his letter, he requested the board to waive the applicable notice period and complete the necessary formalities. The company accepted the resignation with the waiver of the notice period, allowing for an immediate transition effective the close of business hours on September 30, 2026.

Milind Talegaonkar, Company Secretary and Compliance Officer, signed the official communication on behalf of the company. The resignation letter was enclosed with the exchange filing for record purposes.

Key personnel changes

The departure marks a significant leadership change at the pharmaceutical firm, particularly in operational leadership roles. No successor has been named in the current disclosure.

Eris Lifesciences Limited shareholders unanimously adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, during the 20th Annual General Meeting held on September 25, 2026. The meeting, conducted via Video Conferencing, also ratified cost auditor remuneration and approved key director reappointments.

Voting results on financial statements

The resolution to receive, consider, and adopt the audited financial statements along with Board and Auditor reports received overwhelming support. Out of 122,287,170 shares voted through remote e-voting, 122,287,168 shares voted in favor, representing 99.997% of valid votes. Only two members cast negative votes totaling 2 shares. No votes were cast during the live e-voting session via Video Conferencing.

Director reappointments and dissent

Shareholders approved the reappointment of Kaushal Kamlesh Shah (DIN: 01229038), who retired by rotation. While promoters voted entirely in favor, public institutions recorded a 2.83% dissent against this ordinary resolution. Overall, 99.26% of total votes polled supported his reappointment.

A Special Resolution for the reappointment of Sujesh Vasudevan (DIN: 08240092) as an Independent Director saw higher opposition. Public institutions voted 8.90% against the resolution, while non-institutional public shareholders registered a negligible 0.0023% dissent. The final consolidated result showed 97.67% in favor and 2.32% against.

Cost auditor remuneration

The ratification of remuneration for Cost Auditors for the Financial Year ending March 31, 2027, was passed with near-unanimous support. Remote e-voting results showed 100% of valid votes in favor, with only three members casting a combined 26 shares against the resolution.

Governance and compliance details

The proceedings were conducted in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scrutinizer’s report was submitted by Ravi Kapoor & Associates, confirming that no invalid or incomplete votes were found in the e-voting system. The remote e-voting period remained open from September 22, 2026, to September 24, 2026.

Milind Talegaonkar, Company Secretary and Compliance Officer, signed the proceedings digitally on September 25, 2026. The Annual General Meeting commenced at 11:00 am and concluded at 11:30 am.